BACKGROUND: A percent brain volume change (PBVC) cut-off of -0.4% per year has been proposed to distinguish between pathological and physiological changes in multiple sclerosis (MS). Unfortunately, standardized PBVC measurement is not always feasible on scans acquired outside research studies or academic centers. Percent lateral ventricular volume change (PLVVC) is a strong surrogate measure of PBVC, and may be more feasible for atrophy assessment on real-world scans. However, the PLVVC rate corresponding to the established PBVC cut-off of -0.4% is unknown. OBJECTIVE: To establish a pathological PLVVC expansion rate cut-off analogous to -0.4% PBVC. METHODS: We used three complementary approaches. First, the original follow-up-length-weighted receiver operating characteristic (ROC) analysis method establishing whole brain atrophy rates was adapted to a longitudinal ventricular atrophy dataset of 177 relapsing-remitting MS (RRMS) patients and 48 healthy controls. Second, in the same dataset, SIENA PBVCs were used with non-linear regression to directly predict the PLVVC value corresponding to -0.4% PBVC. Third, in an unstandardized, real world dataset of 590 RRMS patients from 33 centers, the cut-off maximizing correspondence to PBVC was found. Finally, correspondences to clinical outcomes were evaluated in both datasets. RESULTS: ROC analysis suggested a cut-off of 3.09% (AUC = 0.83, p < 0.001). Non-linear regression R2 was 0.71 (p < 0.001) and a - 0.4% PBVC corresponded to a PLVVC of 3.51%. A peak in accuracy in the real-world dataset was found at a 3.51% PLVVC cut-off. Accuracy of a 3.5% cut-off in predicting clinical progression was 0.62 (compared to 0.68 for PBVC). CONCLUSIONS: Ventricular expansion of between 3.09% and 3.51% on T2-FLAIR corresponds to the pathological whole brain atrophy rate of 0.4% for RRMS. A conservative cut-off of 3.5% performs comparably to PBVC for clinical outcomes.

Buffalo Neuroimaging Analysis Center Department of Neurology Jacobs School of Medicine and Biomedical Sciences University at Buffalo State University of New York Buffalo NY USA

Buffalo Neuroimaging Analysis Center Department of Neurology Jacobs School of Medicine and Biomedical Sciences University at Buffalo State University of New York Buffalo NY USA; Translational Imaging Center at Clinical and Translational Science Institute University at Buffalo State University of New York Buffalo NY USA

Department of Neurology and Center of Clinical Neuroscience 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Department of Radiology 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Novartis Pharmaceuticals AG Basel Switzerland

QuintilesIMS Basel Switzerland

QuintilesIMS Burlington MA USA

See more in PubMed

Alonso A., Hernán M.A. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology. 2008;71(2):129–135. PubMed PMC

Benedict R.H.B., Zivadinov R. Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat. Rev. Neurol. 2011;7(6):332–342. PubMed

Blatter D.D. Quantitative volumetric analysis of brain MR: normative database spanning 5 decades of life. Am. J. Neuroradiol. 1995;16(2) PubMed PMC

De Stefano N. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 2016;87:93–99. PubMed PMC

Dwyer M.G. Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis. NeuroImage: Clin. 2017;15:769–779. PubMed PMC

Gelineau-Morel R. The effect of hypointense white matter lesions on automated gray matter segmentation in multiple sclerosis. Hum. Brain Mapp. 2012;33(12):2802–2814. PubMed PMC

Giovannoni G. Multiple Sclerosis and Related Disorders. 4(4) 2015. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? pp. 329–333. PubMed

Gyldensted C. Computer tomography of the cerebrum in multiple sclerosis. Neuroradiology. 1976;12(1):33–42. PubMed

Havrdova E. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Mult. Scler. 2009;15(8):965–976. PubMed

Havrdova E. Freedom from disease activity in multiple sclerosis. Neurology. 2010;74(Suppl. 3):S3–7. (17 Suppl 3) PubMed

Hobart J. Timed 25-foot walk direct evidence that improving 20% or greater is clinically meaningful in MS. Neurology. 2013;80(16):1509–1517. PubMed

Horakova D. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study. J. Neurol. Neurosurg. Psychiatry. 2008;79(4):407–414. PubMed

Kappos L. Inclusion of brain volume loss in a revised measure of “no evidence of disease activity” (NEDA-4) in relapsing–remitting multiple sclerosis. Mult. Scler. J. 2016;22(10):1297–1305. PubMed PMC

Kempton M.J. A comprehensive testing protocol for MRI neuroanatomical segmentation techniques: evaluation of a novel lateral ventricle segmentation method. NeuroImage. 2011;58(4):1051–1059. PubMed PMC

Lukas C., Minneboo A., De Groot V. Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 2010;81(12):1351–1356. PubMed

Miller D.H. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain. 2002;125(8):1676–1695. PubMed

van Munster C.E.P., Uitdehaag B.M.J. Outcome measures in clinical trials for multiple sclerosis. CNS Drugs. 2017;31(3):217–236. PubMed PMC

Nakamura K. Jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosis. NeuroImage: Clin. 2014;4:10–17. PubMed PMC

Popescu V. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 2013;84(10):1082–1091. PubMed

Rao S.M. Chronic progressive multiple sclerosis: relationship between cerebral ventricular size and neuropsychological impairment. Arch. Neurol. 1985;42(7):678. PubMed

Sanfilipo M.P. Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis. Neurology. 2006;66(5):685–692. PubMed

Smith S.M. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. NeuroImage. 2002;17(1):479–489. PubMed

Sormani M.P. Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS. Mult. Scler. J. 2016;23(5):656–664. PubMed

Summers M.M. Cognitive impairment in relapsing - remitting multiple sclerosis can be predicted by imaging performed several years earlier. Mult. Scler. 2008;14(2):197–204. PubMed

Tekok-Kilic A. Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis. NeuroImage. 2007;36(4):1294–1300. PubMed

Torkildsen Ø., Myhr K.-M., Bø L. Disease-modifying treatments for multiple sclerosis - a review of approved medications. Eur. J. Neurol. 2016;23(S1):18–27. PubMed PMC

Uher T. Pathological cut-offs of global and regional brain volume loss in multiple sclerosis. Mult. Scler. J. 2017 (ePub ahead of print) PubMed

Vrenken H. Validation of the automated method VIENA: an accurate, precise, and robust measure of ventricular enlargement. Hum. Brain Mapp. 2014;35(4):1101–1110. PubMed PMC

Young I.R. Nuclear magnetic resonance imaging of the brain in multiple sclerosis. Lancet. 1981;318(8255):1063–1066. PubMed

Zivadinov R., Uher T., Hagemeier J. A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients. Mult. Scler. 2016;22(13):1709–1718. PubMed

Zivadinov R. Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. Expert. Rev. Neurother. 2016;16(7):777–793. PubMed

Zivadinov R. An observational study to assess brain MRI change and disease progression in multiple sclerosis clinical practice-the MS-MRIUS study. J. Neuroimaging. 2017;27(3):339–347. PubMed PMC

Zivadinov R. Feasibility of brain atrophy measurement in clinical routine without prior standardization of the MRI protocol: results from MS-MRIUS, a longitudinal. Am. Soc. Neuroradiol. 2018 (Epub ahead of print) PubMed PMC